OmicsBank Secures $2.25M Funding: Leveraging Asian Clinical Data to Accelerate Drug Discovery and AI Development
OmicsBank Secures $2.25M from Redesign Health - HIT Consultant
Summary
OmicsBank, a clinical data infrastructure company, secured $2.25 million in seed funding from global VCs and Redesign Health. The company aims to solve challenges in drug discovery and AI development by utilizing large-scale, standardized electronic health record (EHR) and genomic data primarily from underrepresented regions like South Asia.
Details
OmicsBank is a clinical data infrastructure company connecting fragmented hospital archives. Founded in 2025 by Sumit Sinha and Vijay Goel, the company has deployed its infrastructure across over 90 hospitals and diagnostic laboratories in South Asia, Southeast Asia, and the Middle East. This network includes 12.5 million longitudinal patient records, over 30 million DICOM radiology images, 6 million digitized pathology slides, and 500,000 whole-genome sequences. The core problem OmicsBank addresses is a foundational bias in life sciences: South Asia accounts for nearly 25% of the global population (India alone represents ~20%), yet contributes less than 2% of participants in global genomic studies. OmicsBank structures data at the source into standardized formats, specifically FHIR and OMOP Common Data Model (CDM). The process involves cleaning, indexing, and de-identifying raw records *in-situ* under local standards like IRB, HIPAA, and GDPR before mapping them to these standards. This approach allows it to function as a real-world evidence engine across multiple therapeutic areas, including oncology, neurology, cardiology, etc. The platform packages this multi-modal data into tokenized datasets and GPU-ready compute environments for AI developers, and serves pharma sponsors by identifying diverse clinical trial cohorts and uncovering disease targets. The CEO noted the opportunity to connect this global data foundation with leading health systems as they expand beyond Asia, including the U.S.
Original content copyright by respective publishers